FEXERIC in Slovenian translation

• zdravilo fexeric
• zdravilom fexeric
• zdravila fexeric

Examples of using Fexeric in English and their translations into Slovenian

Fexeric has been administered to over 400 patients≥ 65 years of age in studies where the dose was titrated to achieve target serum phosphorus levels.
V študijah, v katerih so odmerek titrirali za doseganje ciljnih ravni fosforja v serumu, so zdravilo Fexeric uporabili pri več kot 400 bolnikih ≥ 65 let.

Fexeric was shown to be effective at controlling blood-phosphate levels in 2 main studies in patients with long-term kidney disease and hyperphosphataemia.
V dveh glavnih študijah pri bolnikih z dolgotrajno ledvično boleznijo in hiperfosfatemijo so dokazali, da je zdravilo Fexeric učinkovito pri nadzorovanju ravni fosfatov v krvi.

None of the reported serious events in Study 204 were considered to be possibly related to Fexeric.
Noben od poročanih resnih neželenih dogodkov v študiji 204 ni bil povezan z zdravilom Fexeric.

Fexeric must not be used in patients with low blood-phosphate levels,
Zdravilo Fexeric se ne sme uporabljati pri bolnikih z nizkimi ravnmi fosfatov v krvi,

Patients previously on other phosphate binders who are switched to Fexeric should start taking 3 to 6 g(3 to 6 tablets) per day.
Bolniki, ki so predhodno jemali druga zdravila, ki vežejo fosfate, in preidejo na zdravilo Fexeric, morajo začeti jemati od 3 do 6 g(od 3 do 6 tablet) na dan.

The European Medicines Agency has deferred the obligation to submit the results of studies with Fexeric in in one or more subsets of the paediatric population in the treatment of hyperphosphataemia related to chronic kidney disease(see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Fexeric za eno ali več podskupin pediatrične populacije pri zdravljenju hiperfosfatemije, povezane s kronično ledvično boleznijo(za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).

of CKD 5D patients who received Fexeric.
bolnikov s KLB 5D, ki so prejemali zdravilo Fexeric.

the primary evaluation of safety is based on the integrated analysis of data from 4 studies involving 557 CKD 5D patients treated with Fexeric for up to 1 year.
je primarna ocena varnosti temeljila na integrirani analizi podatkov iz 4 študij, ki so vključile 557 bolnikov s KLB 5D, ki so se največ eno leto zdravili z zdravilom Fexeric.

where 75 patients were treated with Fexeric for 12 weeks.
iz ključne študije(študije 204), v kateri so 75 bolnikov 12 tednov zdravili z zdravilom Fexeric.

clinical signs of efficacy if these medicinal products are concomitantly administered with Fexeric.
spremljanju ustreznih označevalcev ali kliničnih znakov učinkovitosti, če se ta zdravila dajejo sočasno z zdravilom Fexeric.

the serum phosphorus levels remained stable in patients receiving Fexeric(mean decrease of 0.24 mg/dl),
so ravni fosforja v serumu pri bolnikih, ki so prejemali zdravilo Fexeric, ostale stabilne(povprečno zmanjšanje za 0,24 mg/dl),

CKD 5D patients treated with Fexeric, compared with patients treated with active control,
bolniki s KLB 5D, zdravljeni z zdravilom Fexeric, v primerjavi z bolniki, zdravljenimi z aktivno kontrolo,

What Fexeric contains.
Kaj vsebuje zdravilo Fexeric.

Other medicines and Fexeric.
Druga zdravila in zdravilo Fexeric.

If you stop taking Fexeric.
Če ste prenehali jemati zdravilo Fexeric.

Fexeric increases iron levels in your body.
Zdravilo Fexeric zviša ravni železa v telesu.

If you take more Fexeric than you should.
Če ste vzeli večji odmerek zdravila Fexeric, kot bi smeli.

Patients must take Fexeric with or immediately after meals.
Bolniki morajo zdravilo Fexeric jemati z obroki ali takoj po njih.

What Fexeric is and what it is used for.
Kaj je zdravilo Fexeric in za kaj ga uporabljamo.

If you take too much Fexeric, tell your doctor of pharmacist.
Če ste vzeli prevelik odmerek zdravila Fexeric, se posvetujte z zdravnikom ali farmacevtom.